| Title |
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
|
|---|---|
| Published in |
Clinical Cancer Research, May 2017
|
| DOI | 10.1158/1078-0432.ccr-17-0408 |
| Pubmed ID | |
| Authors |
Christian P. Kratz, Maria Isabel Achatz, Laurence Brugières, Thierry Frebourg, Judy E. Garber, Mary-Louise C. Greer, Jordan R. Hansford, Katherine A. Janeway, Wendy K. Kohlmann, Rose McGee, Charles G. Mullighan, Kenan Onel, Kristian W. Pajtler, Stefan M. Pfister, Sharon A. Savage, Joshua D. Schiffman, Katherine A. Schneider, Louise C. Strong, D. Gareth R. Evans, Jonathan D. Wasserman, Anita Villani, David Malkin |
| Abstract |
Li-Fraumeni syndrome (LFS) is an autosomal dominantly inherited condition caused by germline mutations of the TP53 tumor suppressor gene encoding p53, a transcription factor triggered as a protective cellular mechanism against different stressors. Loss of p53 function renders affected individuals highly susceptible to a broad range of solid and hematologic cancers. It has recently become evident that children and adults with LFS benefit from intensive surveillance aimed at early tumor detection. In October 2016, the American Association for Cancer Research held a meeting of international LFS experts to evaluate the current knowledge on LFS and propose consensus surveillance recommendations. Herein, we briefly summarize clinical and genetic aspects of this aggressive cancer predisposition syndrome. In addition, the expert panel concludes that there are sufficient existing data to recommend that all patients with LFS be offered cancer surveillance as soon as the clinical or molecular LFS diagnosis is established. Specifically, the panel recommends adoption of a modified version of the "Toronto protocol" that includes a combination of physical exams, blood tests, and imaging. The panel also recommends that further research be promoted to explore the feasibility and effectiveness of these risk-adapted surveillance and cancer prevention strategies while addressing the psychosocial needs of individuals and families with LFS. Clin Cancer Res; 23(11); e38-e45. ©2017 AACRSee all articles in the online-only CCR Pediatric Oncology Series. |
X Demographics
The data shown below were collected from the profiles of 37 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 16% |
| Spain | 3 | 8% |
| Mexico | 3 | 8% |
| Australia | 2 | 5% |
| United Kingdom | 2 | 5% |
| Japan | 1 | 3% |
| Saudi Arabia | 1 | 3% |
| India | 1 | 3% |
| Canada | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 15 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 54% |
| Practitioners (doctors, other healthcare professionals) | 8 | 22% |
| Scientists | 6 | 16% |
| Science communicators (journalists, bloggers, editors) | 3 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 356 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Unknown | 355 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 43 | 12% |
| Other | 42 | 12% |
| Student > Master | 41 | 12% |
| Student > Ph. D. Student | 32 | 9% |
| Student > Bachelor | 25 | 7% |
| Other | 71 | 20% |
| Unknown | 102 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 128 | 36% |
| Biochemistry, Genetics and Molecular Biology | 48 | 13% |
| Agricultural and Biological Sciences | 16 | 4% |
| Nursing and Health Professions | 8 | 2% |
| Engineering | 7 | 2% |
| Other | 29 | 8% |
| Unknown | 120 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 83. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2024.
All research outputs
#520,015
of 25,571,620 outputs
Outputs from Clinical Cancer Research
#273
of 13,264 outputs
Outputs of similar age
#10,759
of 330,761 outputs
Outputs of similar age from Clinical Cancer Research
#9
of 221 outputs
Altmetric has tracked 25,571,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,264 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,761 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 221 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.